Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drugs-SNPs: Alectinib Response and Toxicity in NSCLC
NCT05987956Phase 3Active, not recruiting
- Sponsor
- Medicine Invention Design
- Start
- Mar 2026
- Primary completion
- Nov 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of alectinib in non-small cell lung cancer (NSCLC), sponsored by Medicine Invention Design. Started Mar 2026; status: active, not recruiting.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05987956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05987956.